GE, Theragnostics partner on PSMA agent

By staff writers

October 9, 2019 -- GE Healthcare and Theragnostics have signed a global partnership to develop a new prostate-specific membrane antigen (PSMA) PET/CT imaging agent.

Theragnostics will lead the advancement of the tracer, called GalliProst, while GE will head commercial efforts toward preapproval of the agent and subsequent commercial and distribution activities, if and when regulatory clearance is achieved.

A phase II clinical study to evaluate the efficacy of GalliProst found that one-third of newly diagnosed prostate cancer patients -- more than 50% of whom had biochemically recurrent disease -- had their treatment plans modified as a result of the PSMA agent's findings. The change in patient management increased to 75% after radical radiotherapy.

Copyright © 2019

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking